

**Table 1. Detection of antiviral drug-resistant viruses in Japan during the 2018/2019 influenza season**

as of April 19, 2019

	A(H1N1)pdm09						A(H3N2)						B				
	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir
<b>Resistant (%)</b>	5 <sup>a</sup> (1.9%)	11 <sup>b</sup> (0.7%)	11 <sup>b</sup> (0.7%)	0	0	145 (100%)	28 <sup>c</sup> (10.1%)	0	0	0	0	130 (100%)	0	0	0	0	0
<b>Number of viruses tested</b>	258	1,631	1,631	250	250	145	276	148	148	148	148	130	17	27	27	27	27
<b>Number of viruses reported</b>	2,567						3,466						123				

Baloxavir was examined by focus reduction assay and/or PA sequencing.

NA inhibitors were examined by fluorescence-based NA-Fluor assay, chemiluminescence-based NA-XTD assay, real time RT-PCR allelic discrimination and/or NA sequencing.

Amantadine was examined by M2 sequencing.

<sup>a</sup> Patients without treatment 0

<sup>b</sup> Patients without treatment 1

<sup>c</sup> Patients without treatment 3